Syndax Pharma (SNDX)

$20.81 -0.40 (-1.89%)
Market Cap 1.88B
Revenue (ttm) 172.35M
Net Income (ttm) -285.42M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -165.60%
Debt to Equity Ratio 8.26
Volume 1,229,000
Avg Vol 1,912,916
Day's Range N/A - N/A
Shares Out 88.61M
Stochastic %K 6%
Beta 0.37
Analysts Strong Sell
Price Target $39.00

Company Profile

Syndax Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidate includes Revuforj (revumenib), a menin inhibitor for the treatment of relapsed or refractory R/R acute leukemia; and Niktimvo (axatilimab-csfr), a colony stimulating factor-1 receptor blocking antibody to treat chronic graft-versus-host disease. The company is also developing revumenib for the treatment of R/R acute myeloid leukemia (AML) with a n...

Industry: Biotechnology
Sector: Healthcare
Phone: 781 419 1400
Website: syndax.com
Address:
730 Third Avenue, 9th Floor, New York, United States
dgbio
dgbio Jul. 23 at 10:58 PM
$SNDX Really great results for oral revumenib combo in R/R AML now published as a paper. CR+CRh of 60% vs low twenties for revumenib mono, duration of response of 10+ month vs 4-6 month for mono. https://ascopubs.org/doi/10.1200/JCO-26-01159#xd_co_f=ODQ0NTQ5MTQtN2RlMC00NGUyLTkwYTctNzNmY2I4ZTliZWFm~
1 · Reply
ChartExplorers
ChartExplorers Jul. 23 at 10:30 PM
$SNDX $TGTX .>>
0 · Reply
Doozio
Doozio Jul. 22 at 12:23 AM
$SNDX yes it was. n MAMA 👀 at da cup n handles below da $$$. It can still get LGNDary ENTA 🐒🍌🧠⏰♾️
1 · Reply
OnlyFibs
OnlyFibs Jul. 21 at 10:04 PM
$SNDX combines strong foundational revenue growth with high-impact clinical catalysts. The stock is coiling inside a tight continuation pattern on the 8 hour chart, and market participants are evaluating whether this dip represents the ultimate bottom before the next leg higher. 🐂🎯 Bull Key Levels: A sustained move over 24.00 dollars is essential to clear overhead supply and accelerate upside momentum. 🐂🔥 Bear Key Levels: Defensive bulls need to hold the 20.50 dollar support level at all costs to prevent structural failure. 🐻⚠️ Take Profit Targets: 27.00 / 30.00 dollars. 💰💸 #hovdid $SNDX #stocks #optionsflow #trading
0 · Reply
dgbio
dgbio Jul. 21 at 8:05 PM
$SNDX "Menin inhibitors are poised to play an increasingly important role in the treatment of acute myeloid leukemia (AML) as precision medicine continues to reshape clinical practice". https://www.targetedonc.com/view/the-next-frontier-for-menin-inhibitors-in-aml
0 · Reply
ajmrtxl
ajmrtxl Jul. 17 at 5:29 PM
$SNDX 's latest data on SqueezeFinder
1 · Reply
CNGLLC
CNGLLC Jul. 17 at 12:43 AM
$MU $SNDX $NVDA $SOXL CAN WE BOUNCE NOW ? Thanks
1 · Reply
jeffrman777
jeffrman777 Jul. 16 at 11:16 PM
$SNDX Just gonna wait for earnings here. Meanwhile, macros will be macros.
0 · Reply
PennyPoacher
PennyPoacher Jul. 16 at 9:51 PM
$SNDX OPEX is screening 21 with all those 21c’s just sitting there; we shall see 🤔
0 · Reply
Magnificient
Magnificient Jul. 16 at 5:21 PM
$SNDX waiting for a Entry. My best invest so far
1 · Reply
Latest News on SNDX
Syndax Pharmaceuticals Transcript: R&D Day 2026

Jul 14, 2026, 8:30 AM EDT - 11 days ago

Syndax Pharmaceuticals Transcript: R&D Day 2026

Syndax Pharmaceuticals Slides: FY 2026

Jul 14, 2026, 8:30 AM EDT - 11 days ago

Syndax Pharmaceuticals Slides: FY 2026

Syndax Pharmaceuticals Press release: FY 2026

Jul 14, 2026, 8:30 AM EDT - 11 days ago

Syndax Pharmaceuticals Press release: FY 2026

Syndax to Highlight Late-Stage Programs and Unveil New Pipeline Assets at R&D Event

Jul 14, 2026, 8:00 AM EDT - 11 days ago

Syndax to Highlight Late-Stage Programs and Unveil New Pipeline Assets at R&D Event

Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Jul 1, 2026, 4:01 PM EDT - 23 days ago

Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Syndax price target lowered to $31 from $34 at Guggenheim

2026-06-12T11:11:01.000Z - 6 weeks ago

Syndax price target lowered to $31 from $34 at Guggenheim

KURA

Syndax presents data from SAVE trial at EHA

2026-06-11T12:20:39.000Z - 6 weeks ago

Syndax presents data from SAVE trial at EHA

Syndax Showcases Revuforj® (revumenib) Clinical Activity in Multiple Acute Leukemia Subtypes and Settings at EHA 2026

Jun 11, 2026, 7:03 AM EDT - 6 weeks ago

Syndax Showcases Revuforj® (revumenib) Clinical Activity in Multiple Acute Leukemia Subtypes and Settings at EHA 2026

Syndax Announces Publication of SAVE Data on Revuforj® (revumenib) in Combination with Decitabine/Cedazuridine and Venetoclax in Relapsed/Refractory NPM1m, KMT2Ar, and NUP98r AML in the Journal of Clinical Oncology

Jun 11, 2026, 7:00 AM EDT - 6 weeks ago

Syndax Announces Publication of SAVE Data on Revuforj® (revumenib) in Combination with Decitabine/Cedazuridine and Venetoclax in Relapsed/Refractory NPM1m, KMT2Ar, and NUP98r AML in the Journal of Clinical Oncology

Syndax Pharmaceuticals Transcript: AGM 2026

Jun 10, 2026, 12:00 PM EDT - 6 weeks ago

Syndax Pharmaceuticals Transcript: AGM 2026

Syndax Pharmaceuticals Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026

Jun 8, 2026, 2:00 PM EDT - 6 weeks ago

Syndax Pharmaceuticals Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026

Syndax Pharmaceuticals Transcript: Jefferies Global Healthcare Conference 2026

Jun 4, 2026, 9:20 AM EDT - 7 weeks ago

Syndax Pharmaceuticals Transcript: Jefferies Global Healthcare Conference 2026

Syndax Pharmaceuticals Proxy statement: Proxy filing

Jun 4, 2026, 8:00 AM EDT - 7 weeks ago

Syndax Pharmaceuticals Proxy statement: Proxy filing

Syndax announces $250M convertible senior note offering due 2031

2026-06-04T11:41:28.000Z - 7 weeks ago

Syndax announces $250M convertible senior note offering due 2031

Syndax Announces Private Placement of $250.0 Million of Convertible Senior Notes

Jun 4, 2026, 7:00 AM EDT - 7 weeks ago

Syndax Announces Private Placement of $250.0 Million of Convertible Senior Notes

Syndax Highlights Revuforj® (revumenib) Data Presented at ASCO 2026, Including an Oral Presentation of Post-Transplant Data

Jun 2, 2026, 4:01 PM EDT - 7 weeks ago

Syndax Highlights Revuforj® (revumenib) Data Presented at ASCO 2026, Including an Oral Presentation of Post-Transplant Data

Syndax to Host R&D Day Highlighting its Late-Stage Programs and Early-Stage Assets on July 14, 2026

Jun 1, 2026, 7:00 AM EDT - 7 weeks ago

Syndax to Host R&D Day Highlighting its Late-Stage Programs and Early-Stage Assets on July 14, 2026

Syndax Pharmaceuticals Transcript: 7th Annual Oncology Innovation Summit: Insights for ASCO & EHA

May 27, 2026, 1:00 PM EDT - 2 months ago

Syndax Pharmaceuticals Transcript: 7th Annual Oncology Innovation Summit: Insights for ASCO & EHA

Syndax Announces Four Revuforj® (revumenib) Abstracts Accepted for ASCO 2026, Including an Oral Presentation of Post-Transplant Data

May 21, 2026, 5:01 PM EDT - 2 months ago

Syndax Announces Four Revuforj® (revumenib) Abstracts Accepted for ASCO 2026, Including an Oral Presentation of Post-Transplant Data

Syndax Announces Participation in Upcoming Investor Conferences

May 20, 2026, 7:00 AM EDT - 2 months ago

Syndax Announces Participation in Upcoming Investor Conferences

Syndax price target lowered to $37 from $38 at UBS

2026-05-13T12:20:45.000Z - 2 months ago

Syndax price target lowered to $37 from $38 at UBS

Syndax reports 12 Revuforj abstracts accepted for EHA

2026-05-12T18:34:41.000Z - 2 months ago

Syndax reports 12 Revuforj abstracts accepted for EHA

Syndax Highlights 12 Revuforj® (revumenib) Abstracts Accepted for EHA 2026, Advancing Leadership in Menin Inhibition

May 12, 2026, 10:31 AM EDT - 2 months ago

Syndax Highlights 12 Revuforj® (revumenib) Abstracts Accepted for EHA 2026, Advancing Leadership in Menin Inhibition

Syndax price target raised to $46 from $45 at Stifel

2026-05-04T10:54:25.000Z - 2 months ago

Syndax price target raised to $46 from $45 at Stifel

Syndax price target lowered to $37 from $40 at Jefferies

2026-05-01T19:25:20.000Z - 3 months ago

Syndax price target lowered to $37 from $40 at Jefferies

Syndax price target raised to $37 from $35 at Barclays

2026-05-01T09:40:18.000Z - 3 months ago

Syndax price target raised to $37 from $35 at Barclays

Syndax Pharmaceuticals Earnings Call Transcript: Q1 2026

Apr 30, 2026, 4:30 PM EDT - 3 months ago

Syndax Pharmaceuticals Earnings Call Transcript: Q1 2026

Syndax Pharmaceuticals Earnings release: Q1 2026

Apr 30, 2026, 4:30 PM EDT - 3 months ago

Syndax Pharmaceuticals Earnings release: Q1 2026

Syndax Pharmaceuticals Quarterly report: Q1 2026

Apr 30, 2026, 4:30 PM EDT - 3 months ago

Syndax Pharmaceuticals Quarterly report: Q1 2026

Syndax Pharmaceuticals Slides: Q1 2026

Apr 30, 2026, 4:30 PM EDT - 3 months ago

Syndax Pharmaceuticals Slides: Q1 2026

Syndax Reports First Quarter 2026 Financial Results and Provides Business Update

Apr 30, 2026, 4:01 PM EDT - 3 months ago

Syndax Reports First Quarter 2026 Financial Results and Provides Business Update

Syndax Pharmaceuticals Proxy statement: Proxy filing

Apr 30, 2026, 8:00 AM EDT - 3 months ago

Syndax Pharmaceuticals Proxy statement: Proxy filing

Syndax Pharmaceuticals Proxy statement: Proxy filing

Apr 30, 2026, 8:00 AM EDT - 3 months ago

Syndax Pharmaceuticals Proxy statement: Proxy filing

Syndax to Announce First Quarter 2026 Financial Results and Host Conference Call and Webcast on April 30, 2026

Apr 24, 2026, 7:00 AM EDT - 3 months ago

Syndax to Announce First Quarter 2026 Financial Results and Host Conference Call and Webcast on April 30, 2026

Syndax price target raised to $34 from $28 at Goldman Sachs

2026-03-31T11:13:38.000Z - 4 months ago

Syndax price target raised to $34 from $28 at Goldman Sachs

Syndax price target lowered to $43 from $45 at Mizuho

2026-03-31T11:08:14.000Z - 4 months ago

Syndax price target lowered to $43 from $45 at Mizuho

Syndax assumed with a Buy at Jefferies

2026-03-30T13:08:09.000Z - 4 months ago

Syndax assumed with a Buy at Jefferies

KURA

Syndax Pharmaceuticals Transcript: Barclays 28th Annual Global Healthcare Conference

Mar 12, 2026, 11:00 AM EDT - 4 months ago

Syndax Pharmaceuticals Transcript: Barclays 28th Annual Global Healthcare Conference

Syndax Pharmaceuticals Transcript: Leerink Global Healthcare Conference 2026

Mar 11, 2026, 10:00 AM EDT - 4 months ago

Syndax Pharmaceuticals Transcript: Leerink Global Healthcare Conference 2026

Syndax price target raised to $45 from $33 at JPMorgan

2026-03-09T11:11:49.000Z - 4 months ago

Syndax price target raised to $45 from $33 at JPMorgan

Syndax Pharmaceuticals Transcript: TD Cowen 46th Annual Health Care Conference

Mar 2, 2026, 1:50 PM EST - 5 months ago

Syndax Pharmaceuticals Transcript: TD Cowen 46th Annual Health Care Conference

Syndax price target raised to $57 from $51 at Citi

2026-03-02T11:59:34.000Z - 5 months ago

Syndax price target raised to $57 from $51 at Citi

Syndax Pharmaceuticals Slides: Corporate presentation

Feb 27, 2026, 7:00 AM EST - 5 months ago

Syndax Pharmaceuticals Slides: Corporate presentation

Syndax reports Q4 EPS (78c), consensus (58c)

2026-02-26T21:39:29.000Z - 5 months ago

Syndax reports Q4 EPS (78c), consensus (58c)

Syndax Pharmaceuticals Earnings Call Transcript: Q4 2025

Feb 26, 2026, 4:30 PM EST - 5 months ago

Syndax Pharmaceuticals Earnings Call Transcript: Q4 2025

Syndax Pharmaceuticals Annual report: Q4 2025

Feb 26, 2026, 4:30 PM EST - 5 months ago

Syndax Pharmaceuticals Annual report: Q4 2025

Syndax Pharmaceuticals Earnings release: Q4 2025

Feb 26, 2026, 4:30 PM EST - 5 months ago

Syndax Pharmaceuticals Earnings release: Q4 2025

Syndax Pharmaceuticals Slides: Q4 2025

Feb 26, 2026, 4:30 PM EST - 5 months ago

Syndax Pharmaceuticals Slides: Q4 2025

Syndax Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Feb 26, 2026, 4:01 PM EST - 5 months ago

Syndax Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Syndax Announces Participation in March Investor Conferences

Feb 23, 2026, 7:00 AM EST - 5 months ago

Syndax Announces Participation in March Investor Conferences

Syndax to Announce Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call and Webcast on February 26, 2026

Feb 19, 2026, 7:00 AM EST - 5 months ago

Syndax to Announce Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call and Webcast on February 26, 2026

Syndax Pharmaceuticals Transcript: Guggenheim Securities Emerging Outlook: Biotech Summit 2026

Feb 12, 2026, 12:30 PM EST - 5 months ago

Syndax Pharmaceuticals Transcript: Guggenheim Securities Emerging Outlook: Biotech Summit 2026

Syndax Announces Participation at the 2026 Guggenheim Emerging Outlook: Biotech Summit

Feb 5, 2026, 7:00 AM EST - 6 months ago

Syndax Announces Participation at the 2026 Guggenheim Emerging Outlook: Biotech Summit

Syndax price target raised to $28 from $27 at BofA

2026-02-03T12:36:57.000Z - 6 months ago

Syndax price target raised to $28 from $27 at BofA

Syndax Pharmaceuticals Transcript: 44th Annual J.P. Morgan Healthcare Conference

Jan 12, 2026, 6:00 PM EST - 6 months ago

Syndax Pharmaceuticals Transcript: 44th Annual J.P. Morgan Healthcare Conference

Syndax Pharmaceuticals Slides: 44th Annual J.P. Morgan Healthcare Conference

Jan 12, 2026, 6:00 PM EST - 6 months ago

Syndax Pharmaceuticals Slides: 44th Annual J.P. Morgan Healthcare Conference

Syndax announces expected milestones for 2026

2026-01-12T12:05:54.000Z - 6 months ago

Syndax announces expected milestones for 2026

Syndax Reports Preliminary 2025 Financial Highlights and Provides Business Updates at the 44th Annual J.P. Morgan Healthcare Conference

Jan 12, 2026, 7:00 AM EST - 6 months ago

Syndax Reports Preliminary 2025 Financial Highlights and Provides Business Updates at the 44th Annual J.P. Morgan Healthcare Conference

Syndax, WODA collaborate to launch program to expand access to Revuforj

2026-01-07T12:12:17.000Z - 7 months ago

Syndax, WODA collaborate to launch program to expand access to Revuforj

Syndax and World Orphan Drug Alliance to Launch a Multi-Regional Managed Access Program, Expanding Access to Revuforj® (revumenib) Outside the U.S.

Jan 7, 2026, 7:00 AM EST - 7 months ago

Syndax and World Orphan Drug Alliance to Launch a Multi-Regional Managed Access Program, Expanding Access to Revuforj® (revumenib) Outside the U.S.

Syndax Announces Presentation at the 44th Annual J.P. Morgan Healthcare Conference

Jan 5, 2026, 7:00 AM EST - 7 months ago

Syndax Announces Presentation at the 44th Annual J.P. Morgan Healthcare Conference

Revuforj® (revumenib) Named Best New Drug at the Scrip Awards 2025

Dec 12, 2025, 7:00 AM EST - 8 months ago

Revuforj® (revumenib) Named Best New Drug at the Scrip Awards 2025

Syndax Pharmaceuticals Transcript: Investor Update

Dec 8, 2025, 7:00 AM EST - 8 months ago

Syndax Pharmaceuticals Transcript: Investor Update

Syndax Pharmaceuticals Press release: Investor Update

Dec 8, 2025, 7:00 AM EST - 8 months ago

Syndax Pharmaceuticals Press release: Investor Update

Syndax Pharmaceuticals Slides: Investor Update

Dec 8, 2025, 7:00 AM EST - 8 months ago

Syndax Pharmaceuticals Slides: Investor Update

Syndax Highlights Leadership in Menin Inhibition at ASH 2025 with Multiple Revuforj® (revumenib) Presentations Spanning the Acute Leukemia Treatment Continuum

Dec 8, 2025, 6:50 AM EST - 8 months ago

Syndax Highlights Leadership in Menin Inhibition at ASH 2025 with Multiple Revuforj® (revumenib) Presentations Spanning the Acute Leukemia Treatment Continuum

Syndax Pharmaceuticals Transcript: Evercore ISI 8th Annual HealthCONx Conference

Dec 4, 2025, 11:15 AM EST - 8 months ago

Syndax Pharmaceuticals Transcript: Evercore ISI 8th Annual HealthCONx Conference

Syndax Announces Participation at the 8th Annual Evercore Healthcare Conference

Dec 1, 2025, 7:00 AM EST - 8 months ago

Syndax Announces Participation at the 8th Annual Evercore Healthcare Conference

Syndax Pharmaceuticals Transcript: Jefferies London Healthcare Conference 2025

Nov 20, 2025, 5:00 AM EST - 8 months ago

Syndax Pharmaceuticals Transcript: Jefferies London Healthcare Conference 2025

Syndax Pharmaceuticals Transcript: Stifel 2025 Healthcare Conference

Nov 13, 2025, 10:00 AM EST - 9 months ago

Syndax Pharmaceuticals Transcript: Stifel 2025 Healthcare Conference

Syndax Pharmaceuticals Transcript: Guggenheim Securities 2nd Annual Healthcare Innovation Conference

Nov 11, 2025, 3:00 PM EST - 9 months ago

Syndax Pharmaceuticals Transcript: Guggenheim Securities 2nd Annual Healthcare Innovation Conference

Syndax Pharmaceuticals Transcript: UBS Global Healthcare Conference 2025

Nov 10, 2025, 11:00 AM EST - 9 months ago

Syndax Pharmaceuticals Transcript: UBS Global Healthcare Conference 2025

Syndax Pharmaceuticals Slides: Corporate Presentation

Nov 9, 2025, 6:00 PM EST - 9 months ago

Syndax Pharmaceuticals Slides: Corporate Presentation

Syndax Pharmaceuticals Earnings Call Transcript: Q3 2025

Nov 3, 2025, 4:30 PM EST - 9 months ago

Syndax Pharmaceuticals Earnings Call Transcript: Q3 2025

Syndax Pharmaceuticals Quarterly report: Q3 2025

Nov 3, 2025, 4:30 PM EST - 9 months ago

Syndax Pharmaceuticals Quarterly report: Q3 2025

Syndax Pharmaceuticals Earnings release: Q3 2025

Nov 3, 2025, 4:30 PM EST - 9 months ago

Syndax Pharmaceuticals Earnings release: Q3 2025

Syndax Pharmaceuticals Slides: Q3 2025

Nov 3, 2025, 4:30 PM EST - 9 months ago

Syndax Pharmaceuticals Slides: Q3 2025

Syndax Reports Third Quarter 2025 Financial Results and Provides Business Update

Nov 3, 2025, 4:01 PM EST - 9 months ago

Syndax Reports Third Quarter 2025 Financial Results and Provides Business Update

Syndax Announces Compelling Revuforj® (revumenib) and Niktimvo™ (axatilimab-csfr) Data Accepted for Presentation at ASH 2025

Nov 3, 2025, 9:08 AM EST - 9 months ago

Syndax Announces Compelling Revuforj® (revumenib) and Niktimvo™ (axatilimab-csfr) Data Accepted for Presentation at ASH 2025

Syndax to Host ASH Investor Event in Person and via Webcast on December 8, 2025

Nov 3, 2025, 9:08 AM EST - 9 months ago

Syndax to Host ASH Investor Event in Person and via Webcast on December 8, 2025

Syndax Announces Participation in November Investor Conferences

Oct 30, 2025, 7:00 AM EDT - 9 months ago

Syndax Announces Participation in November Investor Conferences

Syndax to Announce Third Quarter 2025 Financial Results and Host Conference Call and Webcast on November 3, 2025

Oct 27, 2025, 7:00 AM EDT - 9 months ago

Syndax to Announce Third Quarter 2025 Financial Results and Host Conference Call and Webcast on November 3, 2025

Syndax Pharmaceuticals Transcript: Study Update

Oct 24, 2025, 2:30 PM EDT - 9 months ago

Syndax Pharmaceuticals Transcript: Study Update

Syndax Pharmaceuticals Press release: Study Update

Oct 24, 2025, 2:30 PM EDT - 9 months ago

Syndax Pharmaceuticals Press release: Study Update

Syndax Pharmaceuticals Slides: Study Update

Oct 24, 2025, 2:30 PM EDT - 9 months ago

Syndax Pharmaceuticals Slides: Study Update

Syndax Announces FDA Approval of Revuforj® (revumenib) in Adult and Pediatric Patients with Relapsed or Refractory NPM1 Mutated Acute Myeloid Leukemia

Oct 24, 2025, 1:58 PM EDT - 9 months ago

Syndax Announces FDA Approval of Revuforj® (revumenib) in Adult and Pediatric Patients with Relapsed or Refractory NPM1 Mutated Acute Myeloid Leukemia

Syndax's Revuforj® (revumenib) Included in NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for the Treatment of Relapsed or Refractory NPM1 Mutated Acute Myeloid Leukemia

Sep 19, 2025, 7:00 AM EDT - 11 months ago

Syndax's Revuforj® (revumenib) Included in NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for the Treatment of Relapsed or Refractory NPM1 Mutated Acute Myeloid Leukemia

Syndax Pharmaceuticals Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Sep 8, 2025, 9:00 AM EDT - 11 months ago

Syndax Pharmaceuticals Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Syndax Pharmaceuticals Transcript: Citi's Biopharma Back to School Conference

Sep 2, 2025, 4:45 PM EDT - 11 months ago

Syndax Pharmaceuticals Transcript: Citi's Biopharma Back to School Conference

Syndax Announces Participation in September Investor Conferences

Aug 26, 2025, 7:00 AM EDT - 11 months ago

Syndax Announces Participation in September Investor Conferences

Syndax Pharmaceuticals Slides: Corporate Presentation

Aug 19, 2025, 7:00 AM EDT - 1 year ago

Syndax Pharmaceuticals Slides: Corporate Presentation

Syndax Pharmaceuticals Earnings Call Transcript: Q2 2025

Aug 4, 2025, 4:30 PM EDT - 1 year ago

Syndax Pharmaceuticals Earnings Call Transcript: Q2 2025

Syndax Pharmaceuticals Quarterly report: Q2 2025

Aug 4, 2025, 4:30 PM EDT - 1 year ago

Syndax Pharmaceuticals Quarterly report: Q2 2025

Syndax Pharmaceuticals Earnings release: Q2 2025

Aug 4, 2025, 4:30 PM EDT - 1 year ago

Syndax Pharmaceuticals Earnings release: Q2 2025

Syndax Pharmaceuticals Slides: Q2 2025

Aug 4, 2025, 4:30 PM EDT - 1 year ago

Syndax Pharmaceuticals Slides: Q2 2025

Syndax Reports Second Quarter 2025 Financial Results and Provides Business Update

Aug 4, 2025, 4:01 PM EDT - 1 year ago

Syndax Reports Second Quarter 2025 Financial Results and Provides Business Update

Syndax to Announce Second Quarter 2025 Financial Results and Host Conference Call and Webcast on August 4, 2025

Jul 28, 2025, 7:00 AM EDT - 1 year ago

Syndax to Announce Second Quarter 2025 Financial Results and Host Conference Call and Webcast on August 4, 2025

Syndax Announces FDA Priority Review of sNDA for Revuforj® (revumenib) in Relapsed or Refractory mNPM1 Acute Myeloid Leukemia

Jun 24, 2025, 4:01 PM EDT - 1 year ago

Syndax Announces FDA Priority Review of sNDA for Revuforj® (revumenib) in Relapsed or Refractory mNPM1 Acute Myeloid Leukemia

Syndax Announces Publication of Revumenib Data from the BEAT AML Trial in the Journal of Clinical Oncology and Simultaneous Presentation at EHA 2025

Jun 12, 2025, 12:02 PM EDT - 1 year ago

Syndax Announces Publication of Revumenib Data from the BEAT AML Trial in the Journal of Clinical Oncology and Simultaneous Presentation at EHA 2025

Syndax Presents New Revuforj® (revumenib) Data in Relapsed/Refractory mNPM1 and NUP98r Acute Leukemia from AUGMENT-101 Trial at EHA 2025

Jun 12, 2025, 7:00 AM EDT - 1 year ago

Syndax Presents New Revuforj® (revumenib) Data in Relapsed/Refractory mNPM1 and NUP98r Acute Leukemia from AUGMENT-101 Trial at EHA 2025

Syndax Pharmaceuticals Transcript: Goldman Sachs 46th Annual Global Healthcare Conference

Jun 11, 2025, 2:00 PM EDT - 1 year ago

Syndax Pharmaceuticals Transcript: Goldman Sachs 46th Annual Global Healthcare Conference

Syndax Pharmaceuticals Transcript: Jefferies Global Healthcare Conference 2025

Jun 5, 2025, 1:25 PM EDT - 1 year ago

Syndax Pharmaceuticals Transcript: Jefferies Global Healthcare Conference 2025

Syndax Pharmaceuticals Slides: Corporate Presentation

May 30, 2025, 7:00 AM EDT - 1 year ago

Syndax Pharmaceuticals Slides: Corporate Presentation

Syndax Announces Participation in June Investor Conferences

May 29, 2025, 7:00 AM EDT - 1 year ago

Syndax Announces Participation in June Investor Conferences

Syndax Pharmaceuticals Transcript: 6th Annual Oncology Innovation Summit

May 28, 2025, 10:30 AM EDT - 1 year ago

Syndax Pharmaceuticals Transcript: 6th Annual Oncology Innovation Summit

Syndax Pharmaceuticals Transcript: BofA Securities 2025 Healthcare Conference

May 15, 2025, 12:20 PM EDT - 1 year ago

Syndax Pharmaceuticals Transcript: BofA Securities 2025 Healthcare Conference

Syndax Announces Data Presentations at EHA 2025 Showcasing Revuforj® (revumenib) and Niktimvo™ (axatilimab-csfr)

May 14, 2025, 9:30 AM EDT - 1 year ago

Syndax Announces Data Presentations at EHA 2025 Showcasing Revuforj® (revumenib) and Niktimvo™ (axatilimab-csfr)

Syndax Pharmaceuticals Appoints Dr. Nicholas Botwood as Head of Research and Development and Chief Medical Officer

May 12, 2025, 4:01 PM EDT - 1 year ago

Syndax Pharmaceuticals Appoints Dr. Nicholas Botwood as Head of Research and Development and Chief Medical Officer

Syndax Announces Participation in May Investor Conferences

May 8, 2025, 7:00 AM EDT - 1 year ago

Syndax Announces Participation in May Investor Conferences

Syndax Announces Publication of Pivotal Revumenib Data in Relapsed or Refractory mNPM1 Acute Myeloid Leukemia in the Journal Blood

May 7, 2025, 4:01 PM EDT - 1 year ago

Syndax Announces Publication of Pivotal Revumenib Data in Relapsed or Refractory mNPM1 Acute Myeloid Leukemia in the Journal Blood

Syndax Pharmaceuticals Earnings Call Transcript: Q1 2025

May 5, 2025, 4:30 PM EDT - 1 year ago

Syndax Pharmaceuticals Earnings Call Transcript: Q1 2025

Syndax Pharmaceuticals Quarterly report: Q1 2025

May 5, 2025, 4:30 PM EDT - 1 year ago

Syndax Pharmaceuticals Quarterly report: Q1 2025

Syndax Pharmaceuticals Earnings release: Q1 2025

May 5, 2025, 4:30 PM EDT - 1 year ago

Syndax Pharmaceuticals Earnings release: Q1 2025

Syndax Pharmaceuticals Slides: Q1 2025

May 5, 2025, 4:30 PM EDT - 1 year ago

Syndax Pharmaceuticals Slides: Q1 2025

Syndax Reports First Quarter 2025 Financial Results and Provides Business Update

May 5, 2025, 4:01 PM EDT - 1 year ago

Syndax Reports First Quarter 2025 Financial Results and Provides Business Update

Syndax to Announce First Quarter 2025 Financial Results and Host Conference Call and Webcast on May 5, 2025

Apr 28, 2025, 7:00 AM EDT - 1 year ago

Syndax to Announce First Quarter 2025 Financial Results and Host Conference Call and Webcast on May 5, 2025

Syndax Pharmaceuticals Transcript: Stifel 2025 Virtual Targeted Oncology Forum

Apr 9, 2025, 10:30 AM EDT - 1 year ago

Syndax Pharmaceuticals Transcript: Stifel 2025 Virtual Targeted Oncology Forum

Syndax Announces Participation at the Stifel 2025 Virtual Targeted Oncology Forum

Apr 2, 2025, 7:00 AM EDT - 1 year ago

Syndax Announces Participation at the Stifel 2025 Virtual Targeted Oncology Forum

Syndax Pharmaceuticals Proxy statement: Proxy Filing

Apr 1, 2025, 8:00 AM EDT - 1 year ago

Syndax Pharmaceuticals Proxy statement: Proxy Filing

Syndax Pharmaceuticals Proxy statement: Proxy Filing

Apr 1, 2025, 8:00 AM EDT - 1 year ago

Syndax Pharmaceuticals Proxy statement: Proxy Filing

Syndax Pharmaceuticals Transcript: Barclays 27th Annual Global Healthcare Conference

Mar 13, 2025, 8:30 AM EDT - 1 year ago

Syndax Pharmaceuticals Transcript: Barclays 27th Annual Global Healthcare Conference

Syndax Pharmaceuticals Transcript: TD Cowen 45th Annual Healthcare Conference

Mar 4, 2025, 3:10 PM EST - 1 year ago

Syndax Pharmaceuticals Transcript: TD Cowen 45th Annual Healthcare Conference

Syndax Pharmaceuticals Earnings Call Transcript: Q4 2024

Mar 3, 2025, 8:00 AM EST - 1 year ago

Syndax Pharmaceuticals Earnings Call Transcript: Q4 2024

Syndax Pharmaceuticals Annual report: Q4 2024

Mar 3, 2025, 8:00 AM EST - 1 year ago

Syndax Pharmaceuticals Annual report: Q4 2024

Syndax Pharmaceuticals Earnings release: Q4 2024

Mar 3, 2025, 8:00 AM EST - 1 year ago

Syndax Pharmaceuticals Earnings release: Q4 2024

Syndax Pharmaceuticals Slides: Q4 2024

Mar 3, 2025, 8:00 AM EST - 1 year ago

Syndax Pharmaceuticals Slides: Q4 2024

Syndax Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Mar 3, 2025, 7:01 AM EST - 1 year ago

Syndax Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Syndax to Announce Fourth Quarter and Full Year 2024 Financial Results and Host Conference Call and Webcast on March 3, 2025

Feb 24, 2025, 7:00 AM EST - 1 year ago

Syndax to Announce Fourth Quarter and Full Year 2024 Financial Results and Host Conference Call and Webcast on March 3, 2025

Syndax Pharmaceuticals Transcript: Citi's 2025 Virtual Oncology Leadership Summit

Feb 19, 2025, 9:00 AM EST - 1 year ago

Syndax Pharmaceuticals Transcript: Citi's 2025 Virtual Oncology Leadership Summit

Kuehn Law Encourages Investors of Syndax Pharmaceuticals, Inc. to Contact Law Firm

Feb 10, 2025, 5:42 PM EST - 1 year ago

Kuehn Law Encourages Investors of Syndax Pharmaceuticals, Inc. to Contact Law Firm

Syndax Pharmaceuticals Transcript: Guggenheim SMID Cap Biotech Conference

Feb 6, 2025, 10:30 AM EST - 1 year ago

Syndax Pharmaceuticals Transcript: Guggenheim SMID Cap Biotech Conference

Syndax Announces Participation in February Investor Conferences

Jan 30, 2025, 7:00 AM EST - 1 year ago

Syndax Announces Participation in February Investor Conferences

Incyte and Syndax Announce U.S. Food and Drug Administration (FDA) Approval of Niktimvo™ (axatilimab-csfr) 9 mg and 22 mg Vial Sizes

Jan 15, 2025, 5:34 PM EST - 1 year ago

Incyte and Syndax Announce U.S. Food and Drug Administration (FDA) Approval of Niktimvo™ (axatilimab-csfr) 9 mg and 22 mg Vial Sizes

INCY

Syndax Pharmaceuticals Transcript: 43rd Annual J.P. Morgan Healthcare Conference 2025

Jan 14, 2025, 1:30 PM EST - 1 year ago

Syndax Pharmaceuticals Transcript: 43rd Annual J.P. Morgan Healthcare Conference 2025

Syndax Pharmaceuticals Slides: FY 2025

Jan 14, 2025, 1:30 PM EST - 1 year ago

Syndax Pharmaceuticals Slides: FY 2025

Syndax Highlights Recent Accomplishments and Anticipated 2025 Milestones at the 43rd Annual J.P. Morgan Healthcare Conference

Jan 13, 2025, 7:00 AM EST - 1 year ago

Syndax Highlights Recent Accomplishments and Anticipated 2025 Milestones at the 43rd Annual J.P. Morgan Healthcare Conference

Syndax Announces Presentation at 43rd Annual J.P. Morgan Healthcare Conference

Jan 7, 2025, 7:00 AM EST - 1 year ago

Syndax Announces Presentation at 43rd Annual J.P. Morgan Healthcare Conference

dgbio
dgbio Jul. 23 at 10:58 PM
$SNDX Really great results for oral revumenib combo in R/R AML now published as a paper. CR+CRh of 60% vs low twenties for revumenib mono, duration of response of 10+ month vs 4-6 month for mono. https://ascopubs.org/doi/10.1200/JCO-26-01159#xd_co_f=ODQ0NTQ5MTQtN2RlMC00NGUyLTkwYTctNzNmY2I4ZTliZWFm~
1 · Reply
ChartExplorers
ChartExplorers Jul. 23 at 10:30 PM
$SNDX $TGTX .>>
0 · Reply
Doozio
Doozio Jul. 22 at 12:23 AM
$SNDX yes it was. n MAMA 👀 at da cup n handles below da $$$. It can still get LGNDary ENTA 🐒🍌🧠⏰♾️
1 · Reply
OnlyFibs
OnlyFibs Jul. 21 at 10:04 PM
$SNDX combines strong foundational revenue growth with high-impact clinical catalysts. The stock is coiling inside a tight continuation pattern on the 8 hour chart, and market participants are evaluating whether this dip represents the ultimate bottom before the next leg higher. 🐂🎯 Bull Key Levels: A sustained move over 24.00 dollars is essential to clear overhead supply and accelerate upside momentum. 🐂🔥 Bear Key Levels: Defensive bulls need to hold the 20.50 dollar support level at all costs to prevent structural failure. 🐻⚠️ Take Profit Targets: 27.00 / 30.00 dollars. 💰💸 #hovdid $SNDX #stocks #optionsflow #trading
0 · Reply
dgbio
dgbio Jul. 21 at 8:05 PM
$SNDX "Menin inhibitors are poised to play an increasingly important role in the treatment of acute myeloid leukemia (AML) as precision medicine continues to reshape clinical practice". https://www.targetedonc.com/view/the-next-frontier-for-menin-inhibitors-in-aml
0 · Reply
ajmrtxl
ajmrtxl Jul. 17 at 5:29 PM
$SNDX 's latest data on SqueezeFinder
1 · Reply
CNGLLC
CNGLLC Jul. 17 at 12:43 AM
$MU $SNDX $NVDA $SOXL CAN WE BOUNCE NOW ? Thanks
1 · Reply
jeffrman777
jeffrman777 Jul. 16 at 11:16 PM
$SNDX Just gonna wait for earnings here. Meanwhile, macros will be macros.
0 · Reply
PennyPoacher
PennyPoacher Jul. 16 at 9:51 PM
$SNDX OPEX is screening 21 with all those 21c’s just sitting there; we shall see 🤔
0 · Reply
Magnificient
Magnificient Jul. 16 at 5:21 PM
$SNDX waiting for a Entry. My best invest so far
1 · Reply
Magnificient
Magnificient Jul. 16 at 4:39 PM
$SNDX Topline data expected in 4Q26 from Phase 2 trials of axatilimab in IPF and newly diagnosed chronic GVHD –
0 · Reply
chole1
chole1 Jul. 15 at 6:58 PM
$SNDX shorts pressing toward the close?
0 · Reply
Quantumup
Quantumup Jul. 15 at 12:25 PM
H.C. Wainwright reiterated $SNDX Buy-$40 $KURA $AZN ABBV - RHHBY Here's what H.C. Wainwright said in its note: https://x.com/Quantumup1/status/2077368692682195408?s=20
0 · Reply
GeniusLoci
GeniusLoci Jul. 14 at 9:05 PM
$SNDX The company is similar to ITCI, BPMC, and MIRM — all of which featured strong sales in expanding indications with robust pipelines. The outcome? They went from teens to triple digits within a relatively short time, two of the three bought out
1 · Reply
Burning_Cash
Burning_Cash Jul. 14 at 6:16 PM
$SNDX Time to finally break through 25…
0 · Reply
JFais
JFais Jul. 14 at 5:19 PM
$SNDX - as if $INCY needed more reasons to bolster its heme franchise
0 · Reply
BioRich
BioRich Jul. 14 at 4:12 PM
$SNDX I think that the future is not only bright for $SNDX, but strong and foundationalized. I see continued growth for quite some time. I think it's seen as boring in a sector of sexy picks and hype shots at the moon. This is a portfolio anchor stock IMHO. Follow/Subscribe for more suggestion and perspective. Would love to hear yours too. That's how we find these gems and learn. Let's make some (more) money. Cheers!
0 · Reply
JFais
JFais Jul. 14 at 1:56 PM
$SNDX (L) R&D event today- I like that both unveiled assets address areas of high unmet need & moving into clinic relatively soon (vs something not relevant to near-term thesis) Novel menin for MF capitalizes on recent publication, phase 1 to start Q4 with POC data next year!
0 · Reply
jeffrman777
jeffrman777 Jul. 14 at 1:07 PM
$SNDX Not in a rush to sell it seems, which is fine but IPF data better hits and they better keep that growth going.
0 · Reply
Hero2Zero
Hero2Zero Jul. 14 at 12:37 PM
$SNDX just remember - no good R&D day goes unpunished in the biosphere
0 · Reply
GeniusLoci
GeniusLoci Jul. 13 at 9:22 PM
$SNDX iDay tomorrow
0 · Reply
JFais
JFais Jul. 13 at 3:38 PM
Have plenty of positions with outsized gain (ie. $LQDA and $SNDX among others) Just a matter of taking partial profits to rotate $$ into setups currently getting beat up vs holding patiently for continued upside When in doubt, no rush to trade (FOMO's a key weakness of mine)
0 · Reply